Current phase I/II clinical trials that engineer NK-92 cell lines with CARs to target CD19 (NCT02892695), CD33 (NCT02944162), CD7 (NCT02742727) on acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cells are ongoing. The gene discussed is CD7; the disease is acute myeloid leukemia.